---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-078323"
form_type: "8-K"
ticker: "PAHC"
cik: "0001069899"
company_name: "PHIBRO ANIMAL HEALTH CORP"
filed_at: "2026-06-26T21:07:54+00:00"
generated_at: "2026-06-26T21:10:18.582482+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Phibro Animal Health appoints Daniel Bendheim as CEO effective July 1, 2026, with performance-based RSU grant

## Summary
- Daniel Bendheim appointed CEO & President effective July 1, 2026; base salary $850k, target bonus 50% of salary.
- Granted 300,000 performance-based RSUs vesting based on 90-day average stock price from $70 to $100+ by June 30, 2031.
- Severance: 18 months COBRA if terminated without cause; 6 months base salary for death/disability.
- Employment agreement includes confidentiality, non-compete, non-solicitation, non-disparagement covenants.

## SEC filing metadata
- accession: 0001104659-26-078323
- form_type: 8-K
- ticker: PAHC
- cik: 0001069899
- company_name: PHIBRO ANIMAL HEALTH CORP
- filed_at: 2026-06-26T21:07:54+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069899/000110465926078323/0001104659-26-078323-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069899/000110465926078323/tm2619111d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-078323
- JSON: https://secwatch.observer/filing/0001104659-26-078323.json
- Plain text: https://secwatch.observer/filing/0001104659-26-078323.txt

## Key facts
- Executive change
  Daniel Bendheim was appointed as Chief Executive Officer and President at PHIBRO ANIMAL HEALTH CORP.
  - Action: appointed
  - Role: Chief Executive Officer and President
  source text: On June 25, 2026, in connection with Daniel (Dani) Bendheim’s appointment to the role of Chief Executive Officer and President of the Company effective July 1, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069899/000110465926078323/0001104659-26-078323-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.